Fig. 5
A Schematic illustrating 64Cu-labeled trastuzumab PET/CT before and at 30 days after T-DM1/neratinib or T-DM1/lovastatin/neratinib therapy in nu/nu mice bearing NCIN87 tumors. Schematic created using Biorender.com. B Representative PET images of 64Cu-labeled trastuzumab pre-therapy and post-therapy in T-DM1/neratinib or T-DM1/statin/neratinib treatment groups. PET images shown here were calibrated as a percentage of injected dose per mL (%ID/mL) and scaled from 0 (min) to 35 (max). Regions of interest (ROI) were delineated in the tumor, and activity values were obtained as %ID/cm3. The values shown here are expressed as mean uptake %ID/mL in the tumor. C Western blot of tumor lysates collected 63 days after therapy showing phosphorylated HER2, total HER2, and β-actin loading control levels in control, statin, neratinib, statin/neratinib, T-DM1, T-DM1/lovastatin, T-DM1/neratinib, T-DM1/lovastatin/neratinib groups. Full-length blots are included in the Supplementary Information document. Scheme made using Biorender.com.
